Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05016661
Registration number
NCT05016661
Ethics application status
Date submitted
17/08/2021
Date registered
23/08/2021
Date last updated
12/12/2023
Titles & IDs
Public title
Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention
Query!
Scientific title
A Randomized, Multicenter, Dose-Blinded, Phase 2 Extension Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache
Query!
Secondary ID [1]
0
0
ABP-20002
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Migraine
0
0
Query!
Condition category
Condition code
Neurological
0
0
0
0
Query!
Other neurological disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - ABP-450
Experimental: ABP-450 - Low Dose - ABP-450 Low Dose - intramuscular injections into specified muscles.
Experimental: ABP-450 - High Dose - ABP-450 High Dose - intramuscular injections into specified muscles
Treatment: Drugs: ABP-450
ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Incidence of Treatment Emergent Adverse Events
Query!
Assessment method [1]
0
0
The primary safety endpoint will be the incidence of TEAEs throughout the study when dosed with ABP-450 (low dose) or ABP-450 (high dose).
Query!
Timepoint [1]
0
0
Baseline to Week 52 - End of Study
Query!
Primary outcome [2]
0
0
Change in Monthly Migraine Days
Query!
Assessment method [2]
0
0
The primary efficacy endpoint will be the change in mean Monthly Migraine Days (MMD) from Baseline to intervals throughout the study.
Query!
Timepoint [2]
0
0
Baseline to Week 52 - End of Treatment Period
Query!
Secondary outcome [1]
0
0
Percentage of Patients with Reduction in Mean Migraine Days (MMD)
Query!
Assessment method [1]
0
0
Percentage of patients with a reduction from Baseline of = 50 percent, = 75 percent and 100% percent in average number of MMD throughout the study will be assessed by Treatment Group.
Query!
Timepoint [1]
0
0
Baseline to Week 52 - End of Study
Query!
Secondary outcome [2]
0
0
Mean change in Monthly Migraine Days (MMD) requiring medications for acute treatment of migraine or headaches
Query!
Assessment method [2]
0
0
Overall mean change from Baseline in number of MMD requiring migraine specific medication and non-specific medications for the acute treatment of migraine or headache will be assessed by Treatment Group.
Query!
Timepoint [2]
0
0
Baseline to Week 52 - End of Study
Query!
Secondary outcome [3]
0
0
Mean change in Headache Hours
Query!
Assessment method [3]
0
0
Overall mean change from Baseline in headache (either moderate or severe) hours will be assessed by Treatment Group.
Query!
Timepoint [3]
0
0
Baseline to Week 52 - End of Study
Query!
Secondary outcome [4]
0
0
Mean Change in Monthly Headache Days
Query!
Assessment method [4]
0
0
Overall mean change from Baseline in monthly headache days will be assessed by Treatment Group.
Query!
Timepoint [4]
0
0
Baseline to Week 52 - End of Study
Query!
Secondary outcome [5]
0
0
Suicidality by Columbia-Suicide Severity Rating Scale (C-SSRS)
Query!
Assessment method [5]
0
0
Percentage of Participants with Suicidal Ideation and Behaviors will be assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) with the suicidal ideation on a 5-point scale, ranging from "wish to be dead" to "activesuidical ideatikon with specific plan and intert" and suicidal behaviors of a 4-point scale ranging from "preparatory acts or behavior" to "actual attempt" in lifetime, past 3 months, and since last visit. The higher total scores indicate more suicidal ideation and /or suicidal behavior.
Query!
Timepoint [5]
0
0
Baseline to Week 52 - End of Study
Query!
Secondary outcome [6]
0
0
Development of Anti-Drug Antibodies (ADA) to ABP-450
Query!
Assessment method [6]
0
0
Percentage of patients developing Anti-Drug Antibodies to ABP-450 antibodies (binding and if positive, neutralizing) will be assessed.
Query!
Timepoint [6]
0
0
Baseline to Week 52 - End of Study
Query!
Eligibility
Key inclusion criteria
1. Patient can understand the ICF, provides signed ICF and patient privacy information
(eg, Authorization for Use and Release of Health and Research Study Information)
before initiating any study-specific procedure, and agrees to comply with protocol
requirements.
2. Patient was enrolled in Study ABP-20001 and successfully completed that study's
treatment and procedures.
3. A WOCBP must be willing and able to use a medically acceptable and effective method of
birth control, as determined by the investigator, during the entire study.
4. A WOCBP must have a negative urine pregnancy test at Visit 1.
5. Patient can read, understand, and complete the eDiary.
6. Patient is willing and able to adhere to the study assessments, visit schedules, and
prohibitions, as described in this protocol.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Did not meet eligibility criteria for Study ABP-20001 and was improperly enrolled or
randomized in that study.
2. Failure to successfully complete the Study ABP-20001, including the following:
1. use of prohibited medications
2. delay of >4 weeks in receiving second Study ABP-20001 investigational study drug
injection
3. completing fewer than 75% of eDiary entries during the 28-week treatment and
follow-up periods
4. 7 or more consecutive missed days of eDiary entries Note: if the investigator
determines that any of the above 4 failures occurred due to extenuating
circumstances, patients may be allowed to enroll in Study ABP-20002 if the
investigator expects the problem will not recur.
Medical Conditions:
3. History of migraine accompanied by diplopia or decreased level of consciousness, or
retinal migraine.
4. Current diagnosis of chronic tension-type headache, new persistent daily headache,
trigeminal autonomic cephalgia (eg, cluster headache), or cranial neuropathy.
5. Confounding and clinically significant pain syndromes (eg, fibromyalgia, chronic low
back pain, complex regional pain syndromes) as evaluated by the investigator.
6. Diagnosis of myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis,
or any other significant neuromuscular disease that might interfere with the study.
7. Psychiatric conditions that are uncontrolled and/or untreated as evaluated by the
investigator.
8. Lifetime history of psychosis, mania, or dementia.
9. History of addiction, including alcohol or drug abuse since initiating ABP-20001 study
treatment.
10. Any infection or clinically significant skin problem in any of the injection sites.
11. Any medical condition (including but not limited to viral or other active infections)
that, in the opinion of the investigator, classifies the patient as unsuitable for
participation in the study or patients who do not seem to be in good general health at
the time of signing the ICF, and prior to any investigational study drug
administration.
Note: Patients will not routinely be tested for COVID-19 during the study. Patients
presenting with fever or who are symptomatic for COVID-19 will be required to be
tested and treated through their general practitioner.
Other Diagnostic Assessments:
12. Significant risk of self-harm based on clinical interview and responses on the C-SSRS,
or of harm to others in the opinion of the investigator; patients must be excluded if
they report suicidal ideation with intent, with or without a plan (ie, Type 4 or 5 on
the C-SSRS) in the time since enrolling in Study ABP-20001.
Prior/Concomitant Medications and Treatments
13. Injection with anesthesia or steroids in the targeted muscles since initiating
ABP-20001 study treatment.
14. Use of opioids or barbiturates >2 days per month since initiating ABP-20001 study
treatment.
15. Use of CBD or other types of cannabinoids since initiating ABP-20001 study treatment.
16. Use of botulinum toxin for migraine or any other medical reasons, including cosmetic
use, at or above the shoulders outside of Study ABP-20001 since initiating ABP-20001
study treatment and throughout Study ABP-20002.
17. Any CGRP inhibitor treatment (eg, erenumab [Aimovig®], eptinezumab [Vyepti®],
fremanezumab [Ajovy®], or galcanezumab [Emgality®], rimegepant sulfate [Nurtecâ„¢],
ubrogepant [Ubrelvyâ„¢] within or outside of a clinical study) since initiating
ABP-20001 study treatment.
18. Use of small molecule migraine drugs (eg, beta-blockers, anticonvulsants,
antidepressants, calcium channel blockers) since initiating ABP-20001 study treatment.
19. Use of devices for the treatment of migraine (ie, non-invasive neuromodulation
therapies including but not limited to non-invasive nerve stimulation [gammaCore],
transcranial magnetic stimulation [Cefaly], external trigeminal nerve stimulation,
transcutaneous electrical nerve stimulation, and peripheral neuroelectrical
stimulation) since initiating ABP-20001 study treatment.
20. Any other treatments or therapies (eg, acupuncture in head and neck region, cranial
traction, nociceptive trigeminal inhibition, occipital nerve block treatments, and
dental splints for headache) to the head, neck, or shoulder regions since initiating
ABP-20001 study treatment that, in the opinion of the investigator, would interfere
with the investigational study drug.
21. History of inadequate response to 3 classes of medications (which have different
mechanisms of action) prescribed for the prevention of migraine, excluding CGRP
therapies.
22. History of hypersensitivity to human serum albumin, sucrose, or botulinum toxin type
A.
23. Participation in another interventional study since initiating ABP-20001 study
treatment. Other
24. Patients who have been infected with COVID-19 for whom the infection worsened their
migraine disorder. Patients for whom infection with COVID-19 did not worsen their
migraine disorder may be included in the study.
25. Female patients pregnant or planning on becoming pregnant during the study and/or
lactating/breastfeeding.
26. Patient is an employee or family member of the investigator, study site personnel,
PPD, or AEON.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
19/10/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
4/09/2025
Query!
Actual
Query!
Sample size
Target
666
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Liverpool Hospital - Liverpool
Query!
Recruitment hospital [2]
0
0
Grampians Health - Ballarat
Query!
Recruitment hospital [3]
0
0
Emeritus Research - Camberwell
Query!
Recruitment hospital [4]
0
0
Alfred Hospital - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [2]
0
0
3350 - Ballarat
Query!
Recruitment postcode(s) [3]
0
0
3124 - Camberwell
Query!
Recruitment postcode(s) [4]
0
0
3004 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Idaho
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Kansas
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Louisiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Massachusetts
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Michigan
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Missouri
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Nebraska
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Nevada
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New Mexico
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New York
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Ohio
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Pennsylvania
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Tennessee
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Texas
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Utah
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Washington
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Alberta
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Nova Scotia
Query!
Country [26]
0
0
Canada
Query!
State/province [26]
0
0
Ontario
Query!
Country [27]
0
0
Canada
Query!
State/province [27]
0
0
Québec
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
AEON Biopharma, Inc.
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
PPD
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This Phase 2 Extension trial will evaluate the efficacy and safety of ABP-450 for migraine
prevention in adults who suffer from six or more migraine days per month. The study will
enroll approximately 666 patients across approximately 65 sites in the United States, Canada
and Australia from the Phase 2 trial. Study subjects will be divided evenly across a low dose
group and a high dose group. All patients will receive four treatment cycles of ABP-450
utilizing the Company's novel injection paradigm.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05016661
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Richard B Lipton, MD
Query!
Address
0
0
Albert Einstein College of Medicine
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05016661
Download to PDF